Chimeric antigen receptor T cell targeting B cell maturation antigen immunotherapy is promising for multiple myeloma

Immunomodulatory drugs and the risk of serious infection in multiple myeloma: systematic review and meta-analysis of randomized and observational studies

(2018) Min Chen et al.   ANNALS OF HEMATOLOGY

The severe cytokine release syndrome in phase I trials of CD19-CAR-T cell therapy: a systematic review

(2018) Zhen Jin et al.   ANNALS OF HEMATOLOGY

Current developments in immunotherapy in the treatment of multiple myeloma

(2018) Martin Köhler et al.   CANCER

Effective Targeting of Multiple B-Cell Maturation Antigen–Expressing Hematological Malignances by Anti-B-Cell Maturation Antigen Chimeric Antigen Receptor T Cells

(2018) Kevin M. Friedman et al.   HUMAN GENE THERAPY

Emerging immune targets for the treatment of multiple myeloma

(2018) Atif Sohail et al.   Immunotherapy

Lenalidomide plus dexamethasone for patients with relapsed or refractory multiple myeloma: Final results of a non-interventional study and comparison with the pivotal phase 3 clinical trials

(2018) Wolfgang Knauf et al.   LEUKEMIA RESEARCH

Development and Evaluation of an Optimal Human Single-Chain Variable Fragment-Derived BCMA-Targeted CAR T Cell Vector

(2018) Eric L. Smith et al.   MOLECULAR THERAPY

Durable remissions with BCMA-specific chimeric antigen receptor (CAR)-modified T cells in patients with refractory/relapsed multiple myeloma.

(2017) Frank (Xiaohu) Fan et al.   JOURNAL OF CLINICAL ONCOLOGY

A compound chimeric antigen receptor strategy for targeting multiple myeloma

(2017) K H Chen et al.   LEUKEMIA

Immunotherapy in adult acute leukemia

(2017) Sabine Blum et al.   LEUKEMIA RESEARCH

Living with the burden of relapse in multiple myeloma from the patient and physician perspective

(2017) Cyrille Hulin et al.   LEUKEMIA RESEARCH

Chimeric antigen receptor T-cell therapy — assessment and management of toxicities

(2017) Sattva S. Neelapu et al.   Nature Reviews Clinical Oncology

CARs in the Lead Against Multiple Myeloma

(2017) Maria Ormhøj et al.   Current Hematologic Malignancy Reports

Homology-Directed Recombination for Enhanced Engineering of Chimeric Antigen Receptor T Cells

(2017) Malika Hale et al.   Molecular Therapy-Methods & Clinical Development

Multiple myeloma: 2016 update on diagnosis, risk-stratification, and management

(2016) S. Vincent Rajkumar   AMERICAN JOURNAL OF HEMATOLOGY

Therapeutic Potential of T Cell Chimeric Antigen Receptors (CARs) in Cancer Treatment: Counteracting Off-Tumor Toxicities for Safe CAR T Cell Therapy

(2016) Gideon Gross et al.   Annual Review of Pharmacology and Toxicology

Development of chimeric antigen receptors for multiple myeloma

(2016) Carolina Martínez-Cingolani et al.   BIOCHEMICAL SOCIETY TRANSACTIONS

T cells expressing an anti-B-cell maturation antigen chimeric antigen receptor cause remissions of multiple myeloma

(2016) S. A. Ali et al.   BLOOD

Toxicities of chimeric antigen receptor T cells: recognition and management

(2016) Jennifer N. Brudno et al.   BLOOD

Chimeric antigen receptor T cell therapy: 25years in the making

(2016) Saar Gill et al.   BLOOD REVIEWS

The cytological features of CAR(T) cells

(2016) Sarah Brooks et al.   BRITISH JOURNAL OF HAEMATOLOGY

Chimeric Antigen Receptor (CAR) therapy for multiple myeloma

(2016) Djordje Atanackovic et al.   BRITISH JOURNAL OF HAEMATOLOGY

CD19 CAR–T cells of defined CD4+:CD8+ composition in adult B cell ALL patients

(2016) Cameron J. Turtle et al.   JOURNAL OF CLINICAL INVESTIGATION

Early relapse following initial therapy for multiple myeloma predicts poor outcomes in the era of novel agents

(2016) N Majithia et al.   LEUKEMIA

Differentiation stage of myeloma plasma cells: biological and clinical significance

(2016) B Paiva et al.   LEUKEMIA

In Vitro Pre-Clinical Validation of Suicide Gene Modified Anti-CD33 Redirected Chimeric Antigen Receptor T-Cells for Acute Myeloid Leukemia

(2016) Kentaro Minagawa et al.   PLoS One

Immunotherapy for multiple myeloma: Current status and future directions

(2015) Ayed O. Ayed et al.   CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY

Targeting B-cell maturation antigen in multiple myeloma

(2015) Yu-Tzu Tai et al.   Immunotherapy

4-1BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors

(2015) Adrienne H Long et al.   NATURE MEDICINE

Novel anti-B-cell maturation antigen antibody-drug conjugate (GSK2857916) selectively induces killing of multiple myeloma

(2014) Y.-T. Tai et al.   BLOOD

Current concepts in the diagnosis and management of cytokine release syndrome

(2014) D. W. Lee et al.   BLOOD

Widespread Genetic Heterogeneity in Multiple Myeloma: Implications for Targeted Therapy

(2014) Jens G. Lohr et al.   CANCER CELL

Current treatment landscape for relapsed and/or refractory multiple myeloma

(2014) Meletios A. Dimopoulos et al.   Nature Reviews Clinical Oncology

Heterogeneity of genomic evolution and mutational profiles in multiple myeloma

(2014) Niccolo Bolli et al.   Nature Communications

Simultaneous zinc-finger nuclease editing of the HIV coreceptors ccr5 and cxcr4 protects CD4+ T cells from HIV-1 infection

(2013) C. A. Didigu et al.   BLOOD

B-cell Maturation Antigen Is a Promising Target for Adoptive T-cell Therapy of Multiple Myeloma

(2013) R. O. Carpenter et al.   CLINICAL CANCER RESEARCH

Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients

(2013) S K Kumar et al.   LEUKEMIA

Chimeric Antigen Receptor–Modified T Cells for Acute Lymphoid Leukemia

(2013) Stephan A. Grupp et al.   NEW ENGLAND JOURNAL OF MEDICINE

CD19-Targeted T Cells Rapidly Induce Molecular Remissions in Adults with Chemotherapy-Refractory Acute Lymphoblastic Leukemia

(2013) R. J. Brentjens et al.   Science Translational Medicine

Molecular pathogenesis of multiple myeloma and its premalignant precursor

(2012) W. Michael Kuehl et al.   JOURNAL OF CLINICAL INVESTIGATION

B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells

(2011) J. N. Kochenderfer et al.   BLOOD

Treatment Options for Relapsed and Refractory Multiple Myeloma

(2011) Sagar Lonial et al.   CLINICAL CANCER RESEARCH

Multiple Myeloma

(2011) Antonio Palumbo et al.   NEW ENGLAND JOURNAL OF MEDICINE

Relapsed Multiple Myeloma

(2011) S. Lonial   Hematology-American Society of Hematology Education Program

The immortality of humoral immunity

(2010) Raul Elgueta et al.   IMMUNOLOGICAL REVIEWS

Engineering CD19-specific T lymphocytes with interleukin-15 and a suicide gene to enhance their anti-lymphoma/leukemia effects and safety

(2010) V Hoyos et al.   LEUKEMIA

Atacicept in relapsed/refractory multiple myeloma or active Waldenström's macroglobulinemia: a phase I study

(2009) J-F Rossi et al.   BRITISH JOURNAL OF CANCER

Chimeric Receptors Containing CD137 Signal Transduction Domains Mediate Enhanced Survival of T Cells and Increased Antileukemic Efficacy In Vivo

(2009) Michael C. Milone et al.   MOLECULAR THERAPY

CS1, a Potential New Therapeutic Antibody Target for the Treatment of Multiple Myeloma

(2008) E. D. Hsi et al.   CLINICAL CANCER RESEARCH

IRF4 addiction in multiple myeloma

(2008) Arthur L. Shaffer et al.   NATURE